Recombinant Anti-VEGF Receptor 2 antibody [EPRER16Y] (ab134191)
![Western blot - Anti-VEGF Receptor 2 antibody [EPRER16Y] (ab134191)](https://www.abcam.com/ps/products/134/ab134191/Images/ab134191-148522-anti-vegf-receptor-2-antibody-eprer16y-western-blot.jpg "Western blot - Anti-VEGF Receptor 2 antibody [EPRER16Y] (ab134191)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPRER16Y] to VEGF Receptor 2
- Suitable for: ELISA, WB, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-VEGF Receptor 2 antibody [EPRER16Y]
See all VEGF Receptor 2 primary antibodies -
Description
Rabbit monoclonal [EPRER16Y] to VEGF Receptor 2 -
Host species
Rabbit -
Specificity
It is predicted that ab134191 does not cross react with other members of the VEGF receptor family. -
Tested applications
Suitable for: ELISA, WB, IPmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment within Human VEGF Receptor 2 aa 1-800. The exact sequence is proprietary.
-
Positive control
- WB: Human placenta lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPRER16Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab134191 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ELISA |
Use at an assay dependent concentration.
|
|
| WB |
1/1000 - 1/10000. Detects a band of approximately 210, 230 kDa (predicted molecular weight: 151 kDa).
|
|
| IP |
1/20.
|
| Notes |
|---|
|
ELISA
Use at an assay dependent concentration. |
|
WB
1/1000 - 1/10000. Detects a band of approximately 210, 230 kDa (predicted molecular weight: 151 kDa). |
|
IP
1/20. |
Application notes
Is unsuitable for Flow Cyt,ICC/IF or IHC-P.
Target
-
Function
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 3791 Human
- Omim: 191306 Human
- SwissProt: P35968 Human
- Unigene: 479756 Human
-
Alternative names
- CD309 antibody
- CD309 antigen antibody
- EC 2.7.10.1 antibody
see all
Images
-
Western blot - Anti-VEGF Receptor 2 antibody [EPRER16Y] (ab134191)Anti-VEGF Receptor 2 antibody [EPRER16Y] (ab134191) at 1/500 dilution + Human placenta lysate at 10 µg
Secondary
HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 151 kDa
Observed band size: 210,230 kDa why is the actual band size different from the predicted? -
![ELISA - Anti-VEGF Receptor 2 antibody [EPRER16Y] (ab134191)](https://www.abcam.com/ps/products/134/ab134191/Images/ab134191-2-anti-vegf-receptor-2-antibody-eprer16y-elisa-hu-vegfr2.jpg)
ELISA - Anti-VEGF Receptor 2 antibody [EPRER16Y] (ab134191)ELISA analysis of Hu VEGFR2 recombinant protein at 1000 ng/mL with ab134191. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution was used as the secondary antibody. -
![Anti-VEGF Receptor 2 antibody [EPRER16Y] (ab134191)](https://www.abcam.com/ps/products/134/ab134191/Images/ab134191-3-benefits-of-recombinant-antibodies.png)
Anti-VEGF Receptor 2 antibody [EPRER16Y] (ab134191)
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (21)
ab134191 has been referenced in 21 publications.
- Sun X & Liu B Donepezil ameliorates oxygen-glucose deprivation/reoxygenation-induced brain microvascular endothelial cell dysfunction via the SIRT1/FOXO3a/NF-κB pathways. Bioengineered 13:7760-7770 (2022). PubMed: 35286233
- Luo Z et al. LncRNA Meg3 promotes oxygen and glucose deprivation injury by decreasing angiogenesis in hBMECs by targeting the miR‑122‑5p/NDRG3 axis. Exp Ther Med 24:622 (2022). PubMed: 36160904
- Wu Q et al. KIF2A participates in the progression of hepatocellular carcinoma and angiogenesis by interacting with Notch1. Exp Ther Med 24:683 (2022). PubMed: 36277155
- Liang R et al. Dihydroartemisinin inhibits the tumorigenesis and invasion of gastric cancer by regulating STAT1/KDR/MMP9 and P53/BCL2L1/CASP3/7 pathways. Pathol Res Pract 218:153318 (2021). PubMed: 33370709
- Zhang P et al. Distinct mRNAs in Cancer Extracellular Vesicles Activate Angiogenesis and Alter Transcriptome of Vascular Endothelial Cells. Cancers (Basel) 13:N/A (2021). PubMed: 33921957